Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Buys $19,460.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar purchased 7,000 shares of the firm’s stock in a transaction on Thursday, September 24th. The stock was bought at an average price of $2.78 per share, for a total transaction of $19,460.00. Following the completion of the transaction, the chief executive officer directly owned 672,000 shares in the company, valued at approximately $1,868,160. The trade was a 1.05% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Amit Kumar also recently made the following trade(s):

• On Thursday, September 10th, Amit Kumar acquired 3,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $2.75 per share, with a total value of $8,250.00.
• On Thursday, September 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $2.76 per share, with a total value of $13,800.00.
• On Friday, July 31st, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $3.47 per share, with a total value of $17,350.00.
• On Friday, July 24th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $3.73 per share, for a total transaction of $11,190.00.
• On Monday, July 20th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.46 per share, for a total transaction of $17,300.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.44 per share, with a total value of $17,200.00.
• On Friday, July 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.04 per share, with a total value of $15,200.00.

Anixa Biosciences Trading Up 2.8%

Shares of ANIX stock opened at $2.93 on Thursday. Anixa Biosciences Inc has a 12 month low of $2.32 and a 12 month high of $5.46. The company has a market capitalization of $101.85 million, a P/E ratio of -9.16 and a beta of 0.51. The stock has a 50 day moving average of $3.20 and a two-hundred day moving average of $2.97.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). Sell-side analysts predict that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIX. Sanctuary Advisors LLC bought a new position in shares of Anixa Biosciences in the second quarter valued at approximately $29,000. Northwestern Mutual Wealth Management Co. bought a new stake in Anixa Biosciences during the 2nd quarter worth approximately $29,000. Integrated Wealth Concepts LLC bought a new stake in Anixa Biosciences during the 2nd quarter worth approximately $30,000. Simplicity Wealth LLC bought a new stake in Anixa Biosciences during the 2nd quarter worth approximately $34,000. Finally, NewEdge Wealth LLC acquired a new stake in Anixa Biosciences during the 2nd quarter valued at $35,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ANIX has been the topic of several recent research reports. Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Weiss Ratings raised shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. HC Wainwright cut their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, September 22nd. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.00.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.